LATP

LATP:

Two leading products (LTP-0521, and LTP-03) are in pre-clinical stage. The efficacy and toxicity were confirmed in rodent studies. IND-enabling studies of LTP-0521 has been in progress.

LTP-0521
  • Optimized activity on GLP-1R, GCGR, GIPR, and FGF21R
  • Mimics physiological peptide activity, avoiding sustained activation of off-target receptors
  • Effectively reduces body weight in DIO model and preferentially induces fat loss
  • Robust anti-MASH activity with marked reduction in liver fat and fibrosis
  • Limited CNS exposure, exerts mild effects on food intake
  • Similar to native sequence and containing only natural amino acids, thus decreasing any immunogenicity risk
  • Prolonged half-life
  • Produced by recombinant expression without chemical modifications, thus decreasing any immunogenicity risk
  • No safety issues on MASH NHPs up to 3 mg/kg (SC), efficacy and dose escalation studies are on-going
  • Balanced GLP-1R and GCGR activation, and enhanced GIPR activation
  • All natural amino acid and no chemical modifacations renders low immunogenicity
  • Mininal CNS exposure, mild effect on food intake
  • Half-life similar to Semaglutide in mice; Co-administration with Sitagliptin (a DPPIV inhibitor) further extended the half-life.
  • Mimic physiological properties of native peptides: no sustained activation of related receptors
  • Similar physiochemical and pharmacological profiles, and CMC to Dulaglutide
  • Potentially armed with additional metabolic hormones
Scroll to Top